Phase 11b Study of MGC026 Given by IV Infusion in Adults With Advanced or Metastatic Solid Tumors

What this Trial Is About

Researchers are studying MGC026, a drug designed to target advanced solid tumors that are relapsed, refractory, unresectable, locally advanced, or metastatic. This Phase 11b study aims to evaluate the safety, tolerability, how the body processes the drug, immune response, and preliminary antitumor effects. The study includes a dose escalation phase followed by a cohort expansion phase to better understand MGC026s effects in different groups of patients. Participants will receive MGC026 through intravenous infusion every three weeks. The dose will be assigned at enrollment. They may continue treatment for up to 35 cycles as long as there are no severe side effects and the cancer does not worsen. The drug is a topoisomerase 1 inhibitor-based antibody-drug conjugate targeting B7-H3. The study monitors participants for side effects, cancer progression, and collects blood samples for routine lab testing and research. During the study, participants will have regular monitoring for adverse events and cancer status over a period of up to 135 weeks. Blood samples will be taken at scheduled times for pharmacokinetic and immunogenicity analyses. Researchers will assess the number and severity of side effects, response rates, duration of response, and development of antibodies against MGC026. Participants health and safety will be closely observed throughout the trial period.

A Study of MGC026 in Participants With Advanced Solid Tumors